# An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice

> **NCT05526157** · — · COMPLETED · sponsor: **Bayer** · enrollment: 50000 (actual)

## Conditions studied

- Chronic Kidney Disease
- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Finerenone (Kerendia, BAY 948862)
- **DRUG:** Sodium-glucose cotransporter 2 inhibitors (SGLT2i)
- **DRUG:** Glucagon-like peptide-1 receptor agonists (GLP 1 RA)
- **DRUG:** Steroidal mineral corticoid receptor antagonists (sMRA)
- **DRUG:** Non-steroidal mineral corticoid receptor antagonists (nsMRA)

## Key facts

- **NCT ID:** NCT05526157
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-01
- **Primary completion:** 2024-09-05
- **Final completion:** 2024-09-05
- **Target enrollment:** 50000 (ACTUAL)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05526157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05526157, "An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05526157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*